As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative
Vague Definitions, Increasing Uncertainty
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
You may also be interested in...
Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.